Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 5

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 5
---
 $1.00 per share can be deemed by prospective investors as more attractive than the $3.20
price per unit in the primary offering, which can adversely affect the success of our primary offering.

Notwithstanding our belief that upon the effective
date of this registration statement our Common Stock will satisfy the admission requirements for the OTCQB and our intention to make
application for quotation on the OTCQB Market, we cannot assure you that our Common Stock will be quoted on the OTCQB tier. Thereafter,
the Selling Stockholders may sell all or a portion of their Shares through public or private transactions at prevailing market prices
or at privately negotiated prices. The distribution of securities offered hereby may be effected in one or more transactions that may
take place in ordinary brokers’ transactions, privately negotiated transactions or through sales to one or more dealers for resale
of such securities as principals. Usual and customary or specifically negotiated brokerage fees or commissions may be paid by the Selling
Stockholders. The sale of the Shares by Selling Stockholders in the Resale Offering is not conditioned upon the successful completion
of the sale of the Units by the Company in the Primary Offering. The fixed price that the Selling Stockholders can sell their Shares
may be less than the price an investor will pay for the Common Stock in the Primary Offering.

There may be substantial sales of our Common
Stock by the Selling Stockholders after the effective date of this registration statement which could have a material adverse effect
on the price of our Common Stock. See “Substantial future sales or perceived potential sales of Common Stock in the public market could cause the price of the Common Stock to decline” and “There may be substantial sales of our Common Stock by the Selling Stockholders after the effective date of this registration statement of which this prospectus forms a part, which could have a material adverse effect on the price of our Common Stock after the Primary Offering”.

On December 12, 2025, the last reported sale
price for our Common Stock on the OTC Market was $0.52 per share. The Selling Stockholders and any broker-dealers or agents that are
involved in selling the Shares may be deemed to be underwriters within the meaning of the Securities Act in connection with such sales.
In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the Shares purchased by them
may be deemed to be underwriting commissions or discounts under the Securities Act. See“Determination of the Offering Price,” “S